Metastatic Colorectal Cancers Recruiting Phase 3 Trials for Cetuximab (DB00002)

Also known as: Colorectal cancer metastatic / Metastatic Colorectal Cancer

DBCOND0063579 (Metastatic Colorectal Cancers)Recruiting3 IdentifierTitlePurposeDrugs
NCT03391934A Clinical Trial to Determine the Therapeutic Efficacy and Safety Between Cetuximab® (Produced by CinnaGen) and FOLFIRI Compared With Erbitux® (Cetuximab, Produced by Merck Company) and FOLFIRI for RAS Wild-type Metastatic Colorectal Cancer PatientsTreatment
NCT02934529Metastatic Colorectal Cancer (RAS-wildtype) After Response to First-line Treatment With FOLFIR Plus CetuximabTreatment